# Trails Edge Capital Partners, LP 13F Q2 2026: $630 million

Trails Edge Capital Partners, LP reported $630 million in 13F securities across 35 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was LB Pharmaceuticals Inc at $49.4 million, 7.8% of the reported value. Since Q1 2026 it opened 13 new positions and exited 5.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $629,911,888
- Positions: 35
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 2077247
- Form 13F file number: 028-26566
- Business address: 3445 Peachtree Road Ne, Suite 900, Atlanta, GA 30326
- SEC filing: [0002077247-26-000004](https://www.sec.gov/Archives/edgar/data/2077247/000207724726000004/0002077247-26-000004-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/trails-edge-capital-partners-lp-335659)

## Top 25 holdings by value

The largest of 35 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [LB Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/lb-pharmaceuticals-inc-50180m108) | COM SHS | 1,523,022 | $49.4 million | +203,660 |
| [Nurix Therapeutics Inc](https://specstream.ai/data/institutional-holders/nurix-therapeutics-inc-67080m103) | COM | 1,573,220 | $38.2 million | -170,000 |
| [Immunocore Hldgs PLC](https://specstream.ai/data/institutional-holders/immunocore-hldgs-plc-45258d105) | ADS | 1,063,234 | $33.8 million | +380,637 |
| [First Tracks Biotherapeutics](https://specstream.ai/data/institutional-holders/first-tracks-biotherapeutics-337185102) | ORD SHS | 1,514,000 | $30.5 million | New |
| [4d Molecular Therapeutics in](https://specstream.ai/data/institutional-holders/4d-molecular-therapeutics-in-35104e100) | COM | 2,227,917 | $29.6 million | +925,000 |
| [Biomarin Pharmaceutical Inc](https://specstream.ai/data/institutional-holders/biomarin-pharmaceutical-inc-09061g101) | COM | 512,000 | $29.3 million | New |
| [Design Therapeutics Inc](https://specstream.ai/data/institutional-holders/design-therapeutics-inc-25056l103) | COM | 2,001,282 | $29 million | +1,149,269 |
| [Xenon Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/xenon-pharmaceuticals-inc-98420n105) | COM | 440,000 | $26.6 million | No change |
| [Mirum Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/mirum-pharmaceuticals-inc-604749101) | COM | 223,312 | $26.1 million | -110,000 |
| [Insmed Inc](https://specstream.ai/data/institutional-holders/insmed-inc-457669307) | COM PAR $.01 | 230,331 | $24.6 million | New |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 288,089 | $24.5 million | -11,911 |
| [Syndax Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/syndax-pharmaceuticals-inc-87164f105) | COM | 1,110,000 | $24.3 million | +408,179 |
| [Neurogene Inc](https://specstream.ai/data/institutional-holders/neurogene-inc-64135m105) | COM | 714,885 | $22.5 million | -67,902 |
| [Kailera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kailera-therapeutics-inc-482931102) | COMMON STOCK | 984,786 | $21.7 million | New |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 115,750 | $21.7 million | -129,250 |
| [Inhibikase Therapeutics Inc](https://specstream.ai/data/institutional-holders/inhibikase-therapeutics-inc-45719w205) | COM NEW | 9,051,318 | $18.4 million | +993,973 |
| [Incyte Corp](https://specstream.ai/data/institutional-holders/incyte-corp-45337c102) | COM | 155,000 | $17.6 million | New |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 891,881 | $16.5 million | New |
| [Moonlake Immunotherapeutics](https://specstream.ai/data/institutional-holders/moonlake-immunotherapeutics-61559x104) | CLASS A ORD | 750,000 | $14.6 million | New |
| [Faeth Therapeutics Inc](https://specstream.ai/data/institutional-holders/faeth-therapeutics-inc-81728a207) | COM NEW | 515,335 | $12.9 million | +390,335 |
| [X4 Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/x4-pharmaceuticals-inc-98420x202) | COM NEW | 2,571,478 | $12 million | No change |
| [Opus Genetics Inc](https://specstream.ai/data/institutional-holders/opus-genetics-inc-67577r102) | COM | 2,743,658 | $11.3 million | +2,243,658 |
| [Sol-Gel Technologies LTD](https://specstream.ai/data/institutional-holders/sol-gel-technologies-ltd-m8694l137) | SHS NEW | 139,445 | $10.3 million | +53,949 |
| [Aura Biosciences Inc](https://specstream.ai/data/institutional-holders/aura-biosciences-inc-05153u107) | COM | 1,443,333 | $10.2 million | New |
| [Century Therapeutics Inc](https://specstream.ai/data/institutional-holders/century-therapeutics-inc-15673t100) | COM | 4,134,969 | $10.1 million | +1,684,976 |

## New positions in Q2 2026

13 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [First Tracks Biotherapeutics](https://specstream.ai/data/institutional-holders/first-tracks-biotherapeutics-337185102) | ORD SHS | 1,514,000 | $30.5 million |
| [Biomarin Pharmaceutical Inc](https://specstream.ai/data/institutional-holders/biomarin-pharmaceutical-inc-09061g101) | COM | 512,000 | $29.3 million |
| [Insmed Inc](https://specstream.ai/data/institutional-holders/insmed-inc-457669307) | COM PAR $.01 | 230,331 | $24.6 million |
| [Kailera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kailera-therapeutics-inc-482931102) | COMMON STOCK | 984,786 | $21.7 million |
| [Incyte Corp](https://specstream.ai/data/institutional-holders/incyte-corp-45337c102) | COM | 155,000 | $17.6 million |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 891,881 | $16.5 million |
| [Moonlake Immunotherapeutics](https://specstream.ai/data/institutional-holders/moonlake-immunotherapeutics-61559x104) | CLASS A ORD | 750,000 | $14.6 million |
| [Aura Biosciences Inc](https://specstream.ai/data/institutional-holders/aura-biosciences-inc-05153u107) | COM | 1,443,333 | $10.2 million |
| [Altimmune Inc](https://specstream.ai/data/institutional-holders/altimmune-inc-02155h200) | COM NEW | 2,660,000 | $8.1 million |
| [Onkure Therapeutics Inc](https://specstream.ai/data/institutional-holders/onkure-therapeutics-inc-68277q105) | COM CL A | 1,438,456 | $6.6 million |
| [Forte Biosciences Inc](https://specstream.ai/data/institutional-holders/forte-biosciences-inc-34962g208) | COM NEW | 273,181 | $5.8 million |
| [Research Alliance Corp III](https://specstream.ai/data/institutional-holders/research-alliance-corp-iii-g75226103) | ORD SHS CL A | 500,000 | $5.4 million |
| [Imagenebio Inc](https://specstream.ai/data/institutional-holders/imagenebio-inc-45175g207) | COM | 282,004 | $1.7 million |

## Positions exited in Q2 2026

5 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Vaxcyte Inc](https://specstream.ai/data/institutional-holders/vaxcyte-inc-92243g108) | COM | 662,470 | $38.5 million |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 1,738,110 | $32.9 million |
| [Arcus Biosciences Inc](https://specstream.ai/data/institutional-holders/arcus-biosciences-inc-03969f109) | COM | 1,047,935 | $22.6 million |
| Xenon Pharmaceuticals Inc | COM (put) | 200,000 | $11.6 million |
| [Immunovant Inc](https://specstream.ai/data/institutional-holders/immunovant-inc-45258j102) | COM | 414,054 | $10.3 million |

## Also on SpecStream

- [Trails Edge Capital Partners, LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/2077247/000207724726000004/0002077247-26-000004-index.htm)
- [Trails Edge Capital Partners, LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/trails-edge-capital-partners-lp-335659)
- [Largest 13F filers in Georgia](https://specstream.ai/data/institutional-holdings/state/georgia)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Atlanta, Georgia

- [Temp agencies in Atlanta, Georgia](https://specstream.ai/data/businesses/temp-agencies/atlanta-georgia-united-states)
- [Beauty product suppliers in Atlanta, Georgia](https://specstream.ai/data/businesses/beauty-product-suppliers/atlanta-georgia-united-states)
- [Dialysis clinics in Atlanta, Georgia](https://specstream.ai/data/businesses/dialysis-clinics/atlanta-georgia-united-states)
- [Indian restaurants in Atlanta, Georgia](https://specstream.ai/data/businesses/indian-restaurants/atlanta-georgia-united-states)
- [Neurology practices in Atlanta, Georgia](https://specstream.ai/data/businesses/neurology-practices/atlanta-georgia-united-states)
- [Restaurants in Atlanta, Georgia](https://specstream.ai/data/businesses/restaurants/atlanta-georgia-united-states)
